AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO DIAGNOSTIC TECHNOLOGY MEASURING SERUM BIO-MARKER FOR CARDIOVASCULAR INFLAMMATION
DENVER, March 18 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has executed a licensing agreement with the Okayama Prefecture Industrial Promotion Foundation covering new diagnostic technology for serum amyloid protein (SAP), an important serum bio-marker for cardiovascular inflammation. The technology was developed by Dr. Eiji Matsuura at the University of Okayama Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Corgenix has had strategic alliances with researchers and academic institutions in Okayama, Japan, since 2001. The Company's patented AtherOx(TM) technology was developed in collaboration with researchers from the University of Okayama. This new agreement opens additional avenues of technology and strengthens the collaboration with the Okayama Prefecture (a prefecture is the equivalent of a state) aimed at developing innovative and important diagnostic products in the future.
"We are pleased to expand our collaborative relationships in this region. Our alliances have already produced several exciting products, and gaining access to the SAP technology is very promising for our Company," said Douglass Simpson, Corgenix President and Chief Executive Officer. "Serum amyloid proteins are stress proteins typically elevated in bacterial and viral infections, and have been shown to be related to cardiovascular disease as well."
The agreement with Corgenix is the first one established between the
Okayama Prefecture Industrial Promotion Foundation -- a government agency
promoting research and development among industry, universities and
governments -- and a U.S. company. Under the terms of the agreement,
Corgenix has the exclusive rights outside of Japan to further develop the
|SOURCE Corgenix Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved